Released Nov 14, 2023, after the close
10-Q filed Nov 14, 2023, 45 days after period end · 0001493152-23-041124
Q2 2024 · 10-Q
Revenue$14.16M$14.16M +64.9% vs Q2 2023+57.7% vs Q1 2024
Net Income$14.93M$14.93M +885.7% vs Q2 2023+1,208.0% vs Q1 2024
EPS Diluted$0.01$0.01 — vs Q2 2023no prior Q1 2024 on file
Gross Profit$6,447,079+68.6%
Operating Income$1,925,505+78.1%
Operating Cash Flowderived-$235,938N/M
Margins · derived
Gross margin45.5%+1.0 pt vs Q2 2023
Operating margin13.6%+1.0 pt vs Q2 2023
Net margin105.5%+87.8 pt vs Q2 2023
What the release said
The release
Same quarter
| Metric | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|---|
| Revenue | $14.16M | $8.59M | $8.56M | $7.40M |
| Net Income | $14.93M | $1.52M | $1.80M | $2.48M |
| EPS Diluted | $0.01 | $0.00 | $0.00 | $0.00 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Elite Pharmaceuticals Inc · CIK 1053369 · Engraved from SEC EDGAR